Why Pediatrix Medical Group (MD) is a Top Momentum Stock for the Long-Term

Pediatrix Medical Group (MD) is identified as a top momentum stock, currently holding a Zacks #3 (Hold) rank, an 'A' VGM Score, and a 'B' Momentum Style Score. The company has seen its shares rise 3.4% over the past four weeks, supported by an upward revision in its fiscal 2025 earnings estimate to $1.78 per share and a significant average earnings surprise of +28.7%, positioning it as a notable opportunity for momentum-focused investors.

Analysis

Pediatrix Medical Group (MD), which rebranded from Mednax on July 1, 2022, is highlighted as a top momentum stock despite its current Zacks #3 (Hold) rank. The company exhibits strong underlying metrics, including an 'A' VGM Score and a 'B' Momentum Style Score, indicating favorable combined value, growth, and momentum characteristics.

Recent performance shows MD shares have appreciated 3.4% over the past four weeks, aligning with its positive momentum score. Analyst sentiment is also improving, with one analyst revising fiscal 2025 earnings estimates upwards by $0.04 to $1.78 per share within the last 60 days.

Furthermore, Pediatrix boasts a significant average earnings surprise of +28.7%, demonstrating a consistent ability to exceed market expectations. This combination of positive price action, upward earnings estimate revisions, and strong historical earnings beats positions MD as a compelling consideration for momentum-focused investors, despite its neutral Zacks Rank.

Key Decisions for Investors

• Investors should monitor Pediatrix Medical Group (MD) for potential upgrades in its Zacks Rank, given its strong VGM and Momentum Style Scores and positive earnings revisions.
• Consider MD for portfolios seeking momentum plays, particularly given its recent 3.4% price appreciation and consistent positive earnings surprises of +28.7%.
• Evaluate the sustainability of the upward earnings estimate revisions and the company's ability to continue exceeding expectations, which could signal further upside potential.